{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:12:58Z","timestamp":1762431178908},"reference-count":28,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-16-0780","type":"journal-article","created":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T22:03:59Z","timestamp":1473199439000},"page":"2277-2281","source":"Crossref","is-referenced-by-count":45,"title":["Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure"],"prefix":"10.1253","volume":"80","author":[{"given":"Genjiro","family":"Kimura","sequence":"first","affiliation":[{"name":"Asahi Rosai Hospital, Japan Labour Health and Safety Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. <i>N Engl J Med<\/i> 2016; 375: 323\u2013334.","DOI":"10.1056\/NEJMoa1515920"},{"key":"3","unstructured":"3. Maude DL. Salt and water reabsorption. <i>In<\/i>: Maude DL, editor. Kidney Physiology and Kidney Disease. Philadelphia: JB Lippincott, 1977; 17\u201331."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Greger R, Velazquez H. The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism. <i>Kidney Int<\/i> 1987; 31: 590\u2013596.","DOI":"10.1038\/ki.1987.39"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kimura G. Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: Pathophysiological hypothesis. <i>J Am Soc Hypertens<\/i> 2016; 10: 271\u2013278.","DOI":"10.1016\/j.jash.2016.01.009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. <i>J Am Soc Hypertens<\/i> 2014; 8: 330\u2013339.","DOI":"10.1016\/j.jash.2014.02.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. <i>J Am Soc Hypertens<\/i> 2014; 8: 262\u2013275.e269.","DOI":"10.1016\/j.jash.2014.01.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Maliha G, Townsend RR. SGLT2 inhibitors: Their potential reduction in blood pressure. <i>J Am Soc Hypertens<\/i> 2015; 9: 48\u201353.","DOI":"10.1016\/j.jash.2014.11.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? <i>Curr Hypertens Rep<\/i> 2015; 17: 551.","DOI":"10.1007\/s11906-015-0551-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. <i>Diabetes Care<\/i> 2015; 38: 420\u2013428.","DOI":"10.2337\/dc14-1096"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Diabetes Endocrinol<\/i> 2016; 4: 211\u2013220.","DOI":"10.1016\/S2213-8587(15)00417-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 2013; 15: 853\u2013862.","DOI":"10.1111\/dom.12127"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Santer R, Calado J. Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target. <i>Clin J Am Soc Nephrol<\/i> 2010; 5: 133\u2013141.","DOI":"10.2215\/CJN.04010609"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME(R) trial. <i>Eur Heart J<\/i> 2016; 37: 1526\u20131534.","DOI":"10.1093\/eurheartj\/ehv728"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. <i>Hypertension<\/i> 2004; 43: 963\u2013969.","DOI":"10.1161\/01.HYP.0000125726.92964.ab"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. <i>JAMA<\/i> 2003; 289: 2534\u20132544.","DOI":"10.1001\/jama.289.19.2534"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. <i>Hypertension<\/i> 2000; 35: 1025\u20131030.","DOI":"10.1161\/01.HYP.35.5.1025"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Curr Med Res Opin<\/i> 2014; 30: 1759\u20131768.","DOI":"10.1185\/03007995.2014.919907"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: A pooled analysis. <i>Diabetes Ther<\/i> 2016; 7: 125\u2013137.","DOI":"10.1007\/s13300-015-0150-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>Am J Physiol Renal Physiol<\/i> 2015; 309: F889\u2013F900.","DOI":"10.1152\/ajprenal.00267.2015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. <i>Circulation<\/i> 2014; 129: 587\u2013597.","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol<\/i> 2016; 4: 411\u2013419.","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"23","unstructured":"23. Ellison DH. Diuretic resistance: Physiology and therapeutics. <i>Semin Nephrol<\/i> 1999; 19: 581\u2013597."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat: Structural and functional effects of dietary salt intake and chronic diuretic infusion. <i>J Clin Invest<\/i> 1989; 83: 113\u2013126.","DOI":"10.1172\/JCI113847"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chen ZF, Vaughn DA, Beaumont K, Fanestil DD. Effects of diuretic treatment and of dietary sodium on renal binding of 3H-metolazone. <i>J Am Soc Nephrol<\/i> 1990; 1: 91\u201398.","DOI":"10.1681\/ASN.V1191"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)\/Cl(\u2013)-cotransporter abundance: Role of aldosterone. <i>J Am Soc Nephrol<\/i> 2001; 12: 1335\u20131341.","DOI":"10.1681\/ASN.V1271335"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Osmotic diuresis with SGLT2 inhibition: Analysis of events related to volume reduction in dapagliflozin clinical trials. <i>Postgrad Med<\/i> 2016; 128: 346\u2013355.","DOI":"10.1080\/00325481.2016.1153941"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. <i>Lancet<\/i> 1997; 350: 1734\u20131737.","DOI":"10.1016\/S0140-6736(97)05189-1"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/11\/80_CJ-16-0780\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T21:06:38Z","timestamp":1657227998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/11\/80_CJ-16-0780\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-16-0780","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}